Skip to content
The Great News – Lifestyle
Home
Sample Page
Author:
Liminatus Pharma Inc.
Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds
June 3, 2026
Liminatus Pharma Announces Nasdaq Delisting Notification
May 21, 2026
Liminatus Pharma Announces Proposed Merger with InnocsAI to Expand Oncology Cell Therapy Pipeline
May 21, 2026
Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody
March 17, 2026